18.49

6.38% -1.26

After Hours: 18.50 0.01 +0.05%

Newamsterdam Pharma Company Nv (NAMS)

Overview News Price History Financials Why NAMS Down? Discussions Forecast

Newamsterdam Pharma Company Nv stock is traded at $18.49, with a volume of 928.40K. It is down -6.38% in the last 24 hours and down -2.07% over the past month. NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Previous Close:

$19.75

Open:

$20.07

24h Volume:

928.40K

Relative Volume:

1.01

Market Cap:

$2.45B

Revenue:

$14.09M

Net Income/Loss:

$-176.94M

P/E Ratio:

-8.60

EPS:

-2.15

Net Cash Flow:

$-141.24M

1W Performance:

-15.34%

1M Performance:

-2.07%

6M Performance:

-30.51%

1Y Performance:

+3.64%

1-Day Range:

$18.44

$20.11

1-Week Range:

$18.44

$22.00

52-Week Range:

$14.06

$27.29

Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile

Name

Newamsterdam Pharma Company Nv

Sector

Healthcare (1172)

Industry

Biotechnology (662)

Phone

35 206 2971

Address

GOOIMEER 2-35, NARRDEN

Employee

Twitter

Next Earnings Date

Latest SEC Filings

NAMS's Discussions on Twitter

Compare NAMS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NAMS Newamsterdam Pharma Company Nv	18.49	2.45B	14.09M	-176.94M	-141.24M	-2.15
VRTX Vertex Pharmaceuticals Inc	441.99	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	508.86	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	308.71	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	540.71	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	254.09	28.51B	3.81B	-644.79M	-669.77M	-6.24

Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-10-25	Initiated	Stifel	Buy
Jun-04-25	Initiated	Cantor Fitzgerald	Overweight
Dec-30-24	Initiated	H.C. Wainwright	Buy
May-15-24	Initiated	TD Cowen	Buy
Mar-14-24	Initiated	Scotiabank	Sector Outperform
Jan-18-24	Initiated	Guggenheim	Buy
Jan-16-24	Initiated	Piper Sandler	Overweight
Oct-30-23	Initiated	RBC Capital Mkts	Outperform

View All

Newamsterdam Pharma Company Nv Stock (NAMS) Latest News

07:39 AM

Citi initiates NewAmsterdam Pharma stock with buy rating on cholesterol drug - Investing.com Canada

07:39 AM

05:47 AM

Citi Recommends NewAmsterdam Pharma (NAMS) with a Strong Outlook | NAMS Stock News - GuruFocus

05:47 AM

Jun 15, 2025

How the (NAMS) price action is used to our Advantage - news.stocktradersdaily.com

Jun 15, 2025

Jun 14, 2025

Stifel initiates NewAmsterdam stock with Buy rating, $44 target By Investing.com - Investing.com Nigeria

Jun 14, 2025

Jun 13, 2025

NewAmsterdam Pharma’s SWOT analysis: stock poised for cardiovascular breakthrough By Investing.com - Investing.com South Africa

Jun 13, 2025

NewAmsterdam Pharma’s SWOT analysis: stock poised for cardiovascular breakthrough - Investing.com

Jun 13, 2025

NewAmsterdam Pharma’s (NAMS) “Buy” Rating Reaffirmed at Needham & Company LLC - Defense World

Jun 13, 2025

NAMS: Needham Reiterates Buy Rating and Maintains Price Target | - GuruFocus

Jun 13, 2025

Jun 12, 2025

Cantor Fitzgerald maintains NewAmsterdam Pharma stock rating on trial data By Investing.com - Investing.com India

Jun 12, 2025

NewAmsterdam Pharma stock maintains buy rating at Stifel on strong data - Investing.com Nigeria

Jun 12, 2025

Cantor Fitzgerald maintains NewAmsterdam Pharma stock rating on trial data - Investing.com

Jun 12, 2025

California State Teachers Retirement System Raises Position in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World

Jun 12, 2025

Jun 11, 2025

13 Biotech Stocks with Huge Upside Potential - Insider Monkey

Jun 11, 2025